Lilly Profit Beats Analyst Estimates as Cymbalta Sales Climb

Lilly Profit Beats Analyst Estimates as Cymbalta Sales Climb

JB Reed/Bloomberg

Revenue fell 1 percent to $5.96 billion, beating analysts’ average estimate of $5.8 billion as sales of its top-selling product, the Cymbalta depression treatment, increased.